Selective elimination of leukemia stem cells: Hitting a moving target
- 10 September 2013
- journal article
- review article
- Published by Elsevier BV in Cancer Letters
- Vol. 338 (1), 15-22
- https://doi.org/10.1016/j.canlet.2012.08.006
Abstract
No abstract availableKeywords
This publication has 93 references indexed in Scilit:
- Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CMLCell Stem Cell, 2012
- Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with ImatinibCancer Cell, 2012
- IL-6 Controls Leukemic Multipotent Progenitor Cell Fate and Contributes to Chronic Myelogenous Leukemia DevelopmentCancer Cell, 2011
- DNA Damage-Mediated Induction of a Chemoresistant NicheCell, 2010
- The bone marrow microenvironment as a sanctuary for minimal residual disease in CMLBiochemical Pharmacology, 2010
- Critical molecular pathways in cancer stem cells of chronic myeloid leukemiaLeukemia, 2010
- Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib MesylateCancer Cell, 2010
- Key Roles for Transforming Growth Factor β in Melanocyte Stem Cell MaintenanceCell Stem Cell, 2010
- A Wnt Survival Guide: From Flies to Human DiseaseJournal of Investigative Dermatology, 2009
- Loss of β-Catenin Impairs the Renewal of Normal and CML Stem Cells In VivoCancer Cell, 2007